AstraZeneca looks to N-Side for ‘a single source of truth’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/ChrisGorgio)
(Image: Getty/ChrisGorgio)

Related tags: Astrazeneca, N-Side, Supply chain

AstraZeneca is implementing N-Side’s recently launched Suite for Clinical Trials to provide ‘a single source of truth’ for safely supplying trials, as more stakeholders are generating more data.

AstraZeneca will use the N-Side Supply and Dashboard Apps to design, plan, and monitor its clinical trial supply chain, according to N-Side, which has been providing consulting services for AstraZeneca since 2017.

N-Side’s Life Sciences Director, Sébastien Coppe, described the suite as an “innovative digital platform that empowers decision makers to optimize their clinical supplies decisions and efficiently communicate with other stakeholders.”

The N-Side suite enables customers to see ‘where and when’ a drug supply shortage could potentially occur – providing actions to mitigate the risks and an average 30% budget reduction compared to existing solutions, according to the company.

“Shorter shelf life of drugs, more expensive comparator drugs used in the clinical trials, and limited biotech drug production capacity make it more important than ever to have a reliable clinical supply plan that reduces drug waste while managing the risk to patient service levels,”​ Sylvia Haller, life sciences marketing manager at N-Side, told us.

The global software consulting company launched​ the end-to-end clinical trial supply chain management solution in March of this year.

According to the Belgium-based company, the N-Side Suite for Clinical Trials uses data analytics and machine learning (ML) algorithms to support decision making and builds on the company’s existing CT-Fast solution for supply forecasting.

“As more and more data is generated and managed by different stakeholders in clinical trials, it is more important than ever to have a single source of truth for safely supplying the trial,” ​Haller added, “which allows efficient communication channels between clinical and supply departments.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more